The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error. Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials. Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies. This podcast is for you if: You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership You are a
Pitch Analysis
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
36%
Guest openness
Selective
Verified email on file
85/100
Required Score
Sign up to generate a grounded pitch for Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders.
What is Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders?
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders is a science podcast hosted by Unknown Host, with 289 episodes on record and a Required Pod Score of 85.
About the host
Unknown Host hosts Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders, a science show with 289 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #291
291: The Fool's Game That Became Standard Practice: Perfusion, the ATF, and What Changed with John Bonham-Carter - Part 1
Sep 28, 202631 min
Biotech loves talk of disruptive technology, but few have repeatedly shifted the industry's direction. This episode of the Smart Biotech Scientist Podcast focuses on an idea once dismissed as a fool's game: process intensification through perfusion—now the backbone of leading biomanufacturing platforms. Meet John Bonham-Carter, a serial entrepreneur whose fingerprints are on some of biotech's most transformative tools. From putting the once-ignored ATF system and perfusion on the global stage to pushing intensified cell therapy bioprocessing with ERBI, John's story isn't about chasing the next big exit. Instead, it's about spotting unmet needs and building and selling biotools companies more than once. Topics discussed: The story behind the ATF system, and how John Bonham-Carter and his collaborators convinced a conservative industry to adopt perfusion (04:43) Early career influences, including family ties to bioprocess equipment manufacturing (05:03) Reflections on the biotech industry’s culture of collaboration and the dual motivation to deliver medicines and achieve commercial success (07:18) Realities of scaling a startup, trading income for equity, and the role of persistence in sales (09:34) Lessons learned from global travel and building professional networks in biotech (10:16) The importance of recognizing what drives different biotech companies to adopt new technology (12:25) The transition from ATF to co-founding Erbi, a bioprocessing startup focused on small-volume cell therapy (19:05) Strategic acquisitions: experiences of being acquired by Repligen and Merck Millipore (22:50) Advice for founders on whether to build a company for exit or long-term operation (23:07) The limits of leading with technology, and why customer understanding is critical to success (26:10) Smart insight: For founders, John Bonham-Carter offers practical guidance anchored in self-awareness. Should you build a company for the long haul or for acquisition? The answer: “There isn’t really a right answer...it is, what is the life you want to lead?” Some entrepreneurs thrive at the scale of ten-person teams and relish the handoff to a strategic acquirer. Others yearn to build and steer a 200-person enterprise. Regardless, serving customers and employees well, and being attuned to the market’s shifting demands, matter most. Exit opportunities arise from building value and strategic fit—not from fixating on selling out. Some ideas are ahead of their time; a few people make a career of being early. This is part bioprocess history, part founder's playbook: why the best technology doesn't automatically win, how to move a conservative industry, and when to sell rather than scale. To go further on both the technology and the business behind it: Episodes 191 - 192: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas Castan Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) Connect with John Bonham-Carter: Website: www.stellion-biosystems.com LinkedIn: www.linkedin.com/in/johnbc Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show
290: Batch-to-Batch Variability Is a Design Failure, Not the Norm with Sandra Núñez - Part 2
Sep 23, 202620 min
What if building a world-class biotech company didn’t require owning a single piece of manufacturing equipment or even a lab of your own? Most startups obsess over bricks, mortar, and stainless steel. Not Sandra Núñez. She’s challenging the status quo as CEO of Amela Biosciences by running a “virtual plant” model: zero in-house production, everything outsourced, and agility baked into every decision. It’s a bold experiment in redefining what a biotech company can look like. One that’s already delivering real, animal-free products to customers today. Topics discussed: Key considerations and pitfalls in tech transfer from academic labs to external CDMO partners (02:34) The reasoning behind choosing a virtual plant model with no in-house manufacturing (04:57) Criteria for selecting external manufacturing partners, including technical capabilities and cultural fit (06:28) Stakeholder communications and managing misconceptions about outsourced manufacturing (07:44) Process development challenges when scaling products for commercial use, including impurity profile and scalability of purification methods (08:53) Early preparations for future GMP manufacturing and building a foundation for regulatory compliance (11:20) The impact of regulatory shifts (like the FDA Modernization Act 2.0) on manufacturing strategy and product reproducibility (12:47) Hopes for the company’s future role in the transition to animal-free and regenerative medicine (14:19) Practical advice for startup founders considering a leap from corporate biotech to entrepreneurship (15:09) Reflections on the importance of addressing batch-to-batch variability and building reproducible systems (16:40) Smart insight: Don’t accept batch-to-batch variability. Reproducibility is non-negotiable. Batch-to-batch variability, whether in raw materials or process design, is a critical risk that forward-thinking should design out, not accept as inevitable. As Sandra concludes, reproducibility isn’t just a lab problem, it’s a company-building problem, one that shapes strategy, manufacturing partnerships, and regulatory success. Here are four episodes that pick up the same threads: animal-free matrices, reproducibility by design, and building a biotech without a factory: Episodes 271 - 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito Episodes 275 - 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet Episodes 279 - 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher Connect with Sandra Núñez: Website: www.amelabiosciences.com Company LinkedIn: www.linkedin.com/company/amela-biosciences-ag Sandra’s LinkedIn: www.linkedin.com/in/sandra-nunez-ch Sandra’s email: s.nunez@amelabiosciences.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show
289: Batch-to-Batch Variability Is a Design Failure, Not the Norm with Sandra Núñez - Part 1
Sep 21, 202619 min
Batch-to-batch variability isn’t just a minor annoyance in bioprocess development; it’s often a systemic design flaw hiding in plain sight. That’s the challenge Sandra Núñez, CEO of Amela Biosciences, set out to eliminate. Drawing on 15 years across Lonza, Medinova, Baxalta, and Biogen, she’s engineered a new generation of animal-free, recombinant protein matrices that promise researchers experimental consistency on demand. Topics discussed: The widespread issue of batch-to-batch variability and why Sandra argues it’s a design failure, not the norm (02:49) The mechanics and biological tunability of Amela’s engineered protein matrices, and how this technology works (06:34) How Amela’s recombinant protein bioinks differ from traditional animal-sourced extracts, enabling reproducibility (08:53) Manufacturing insights: why the proteins are relatively straightforward to produce for research use (12:05) Engaging with users to optimize and customize protein matrices for diverse tissue and assay applications (13:33) The creation and use of protein libraries for specific user requirements and the flexibility this provides (16:20) Definitions and roles of ‘bioinks’ in tissue modeling and 3D cell culture (16:52) Smart insight: Reproducibility remains the cornerstone of reliable science. With innovative platforms like Amela Biosciences’ engineered protein matrices, the future of tissue engineering and in vitro biology looks not just reliable, but radically empowering. If you’re striving for consistency, customizability, and cutting-edge technology in your workflows, the era of animal-free, batch-consistent bioinks has arrived. Here are four episodes that pick up the same threads: animal-free matrices, reproducibility by design, and building a biotech without a factory: Episodes 271 - 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito Episodes 275 - 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet Episodes 279 - 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher Connect with Sandra Núñez: Website: www.amelabiosciences.com Company LinkedIn: www.linkedin.com/company/amela-biosciences-ag Sandra’s LinkedIn: www.linkedin.com/in/sandra-nunez-ch Sandra’s email: s.nunez@amelabiosciences.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show
288: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 2
Sep 16, 202622 min
Manufacturability challenges in biotech are becoming more complex as therapies become more potent, formats diversify, and timelines compress across the industry. On this episode, David Brühlmann sits down with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. Sigma brings deep expertise in early-stage CMC decision-making and has guided countless programs—from upstart startups to established pipelines—through the traps and trade-offs of process development. Her ground-floor perspective spans in silico modeling, innovative cell line engineering, and the gritty realities of tech transfer. Key topics discussed: Practical advice for startups on selecting robust cell lines and avoiding long-term lock-in to problematic platforms (03:07) Managing risks in process development, such as high oxygen demand and filter loading, before tech transfer to manufacturing (04:47) The value of pressure testing bioprocesses at scale and identifying potential failure modes, including filter clogging and narrow feeding windows (07:41) Balancing speed, robustness, and regulatory expectations when advancing new molecules (09:23) How fast-tracking from transfection to IND is changing timelines, and the associated risks of accelerated development (09:54) Trends and caution in applying AI and in silico tools to protein and process modeling, and the limits of digital solutions (12:01) What first-time founders need to get right, including early analysis of molecular issues and careful cell line selection (15:48) Shifting modality trends—growing numbers of ADCs/XDCs, more complexity, and the move toward smaller scale and more potent molecules (16:55) The overarching lesson: invest early in the areas you cannot change later—especially cell line and understanding of molecule challenges (18:23) Smart insight: Startup founders often wonder which fires to fight first. Sigma’s advice: focus on deep molecular assessment and making informed, scalable cell line choices above all else. These are the “few things you cannot change later” and the investments that separate enduring programs from cautionary tales. This episode unpacks what that means in practice and where speed and robustness pull against each other. If it resonated, these conversations expand the picture: how to spot manufacturable candidates early, how in silico tools predict stability and aggregation before the lab, and which early CMC decisions quietly become permanent. Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa Connect with Sigma Mostafa: Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817 KBI website: https://www.kbibiopharma.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show
287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1
Sep 14, 202618 min
A breakthrough in drug discovery can be derailed in an instant if manufacturability is left as an afterthought. Too many biotech programs hit bottlenecks at scale-up because key decisions in cell line and process development get kicked down the road. On the Smart Biotech Scientist Podcast, David Brühlmann spoke with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. She’s spent 25+ years converting early-stage discoveries into commercial biomanufacturing success and she’s adamant: manufacturability decisions belong at the candidate selection stage, not after. Topics discussed: Why manufacturability should be assessed at the candidate selection stage, not later (03:02) Sigma’s background in bringing math and biology together and her path into bioprocess engineering (04:18) The "art" and complexity of bioprocess development, especially with new molecule types (05:54) A case study of how switching cell lines revealed hidden manufacturability issues (07:33) Key properties affecting manufacturability, such as aggregation and thermal stability (10:10) Reasons companies delay manufacturability assessments—timing pressure, costs, and lack of early deep characterization (11:02) Why CMC should be integrated from day one and concerns with treating scalability as 'just' engineering (12:08) Critical decisions and pitfalls in cell line development, including robustness, media choices, and adapting after the master cell bank is made (12:48) Regulatory aspects of cell line development: demonstrating clonality, avoiding animal source materials, and documentation requirements (15:04) Smart insight: Manufacturability is not just a box for the CMC team. It’s a proactive mindset, to be embraced from day one. Early, cross-functional scrutiny—examining both molecule and cell line—preempts disasters during scale-up and accelerates timelines to market while minimizing costly surprises. This episode unpacks what that means in practice and where speed and robustness pull against each other. If it resonated, these conversations expand the picture: how to spot manufacturable candidates early, how in silico tools predict stability and aggregation before the lab, and which early CMC decisions quietly become permanent. Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa Connect with Sigma Mostafa: Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817 KBI website: https://www.kbibiopharma.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show
Recent guests on Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders. Study who booked and why before you pitch.
Every question we get asked before someone starts their trial.
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
What is the difference between Founder Solo and Founder Pro?
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
How do agency tiers work?
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
What is a talent profile?
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Can I switch plans later?
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Do you offer a free trial?
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
What happens if I cancel?
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Is the 20% annual discount automatic?
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
What if I have more than 50 profiles or 20 clients?
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
